Stay updated on Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Sign up to get notified when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.

Latest updates to the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedA new Locations section was added listing study sites in Minnesota, New Jersey, New York, Pennsylvania, and Utah, and state-specific location subsections were removed. The page revision updated to v3.3.3.SummaryDifference0.6%

- Check19 days agoNo Change Detected
- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedAdded a note that publications are automatically filled from PubMed, and updated the page revision to v3.3.2 (replacing the previous v3.2.0 wording). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedRemoved the government operating-status notice about funding and NIH updates. The page now shows only the study details without the prior operational disclaimer.SummaryDifference0.3%

- Check69 days agoChange DetectedNo observable changes to the Study Details page; all sections and information appear unchanged.SummaryDifference0.4%

- Check91 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision. The page now communicates potential service delays and open NIH Clinical Center status, plus the updated software version.SummaryDifference3%

- Check98 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

Stay in the know with updates to Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Emapalumab & Anakinra for COVID-19 Hyperinflammation Clinical Trial page.